Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special populations and label expansion studies with the fixed dose combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique.

X
Trial Profile

Special populations and label expansion studies with the fixed dose combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artemether/lumefantrine (Primary) ; Artesunate/amodiaquine (Primary) ; Dihydroartemisinin/piperaquine (Primary) ; Efavirenz; Lamivudine/stavudine; Lamivudine/stavudine/nevirapine; Lamivudine/zidovudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications Malaria
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ADAPT
  • Most Recent Events

    • 27 Aug 2018 Results published in the Antimicrobial Agents and Chemotherapy
    • 14 May 2018 Results from 2 studies (PACTR2010030001871293, n=18 and PACTR2010030001971409, n=75) assessing pharmacokinetics and safety profiles published in the Antimicrobial Agents and Chemotherapy
    • 13 Feb 2013 Planned number of patients changed from 66 to 74 as reported by Pan-African Clinical Trials Registry.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top